Nexalin Technology, Inc. announced that it has commenced sales of its second generation (Gen-2), 15 milliamp (mA) neurostimulation device into a new mental health center in Oman, dedicated to the use of Nexalin?s neurostimulation device for the treatment of patients with substance abuse disorder (SUD). The new clinic opened and commenced treatment of patients with Nexalin?s Gen-2 neurostimulation device following a successful evaluation and inspection of the facility by the Sultanate of Oman?s Ministry of Health, which ensures strict quality standards and adherence to established and robust guidelines and regulations.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.06 USD | -7.83% | -22.06% | +161.86% |
05-10 | Nexalin Technology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-25 | Nexalin Technology Regains Compliance With Nasdaq Listing Requirement | MT |
1st Jan change | Capi. | |
---|---|---|
+161.86% | 8.55M | |
+10.22% | 226B | |
+12.99% | 198B | |
+18.09% | 142B | |
+28.66% | 111B | |
+2.09% | 65.26B | |
+14.70% | 54.36B | |
+6.68% | 50.94B | |
+8.29% | 44.8B | |
+2.60% | 36.8B |
- Stock Market
- Equities
- NXL Stock
- News Nexalin Technology, Inc.
- Nexalin Technology, Inc. Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman